Source 1primary paper2025MED
Toolkit/lipid-polymer hybrid nanoparticles
lipid-polymer hybrid nanoparticles
Also known as: LPHNPs, RNA-LPHNPs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Lipid-polymer hybrid nanoparticles (LPHNPs) are the next-generation nanocarriers that integrate the mechanical strength and sustained-release capacity of polymeric cores with the biocompatibility and high drug-loading efficiency of lipid shells.
Usefulness & Problems
Why this is useful
LPHNPs are RNA delivery platforms that combine lipid and polymer components to encapsulate RNA, support site-specific delivery, and control RNA release. The abstract presents them as modular carriers for mRNA or siRNA across multiple disease contexts and administration routes.; RNA therapeutic delivery across diverse biomedical applications; local or systemic delivery of mRNA or siRNA; delivery across oral, inhaled, intravenous, and intravesical administration routes; LPHNPs are nanocarriers built from polymeric cores and lipid shells. The abstract describes them as combining mechanical strength and sustained release with biocompatibility and high drug-loading efficiency.; delivery of diverse therapeutic agents; delivery of poorly soluble drugs; delivery of phytochemicals; delivery of genetic materials; ocular, topical, and oral delivery
Source:
LPHNPs are RNA delivery platforms that combine lipid and polymer components to encapsulate RNA, support site-specific delivery, and control RNA release. The abstract presents them as modular carriers for mRNA or siRNA across multiple disease contexts and administration routes.
Source:
RNA therapeutic delivery across diverse biomedical applications
Source:
local or systemic delivery of mRNA or siRNA
Source:
delivery across oral, inhaled, intravenous, and intravesical administration routes
Source:
LPHNPs are nanocarriers built from polymeric cores and lipid shells. The abstract describes them as combining mechanical strength and sustained release with biocompatibility and high drug-loading efficiency.
Source:
delivery of diverse therapeutic agents
Source:
delivery of poorly soluble drugs
Source:
delivery of phytochemicals
Source:
delivery of genetic materials
Source:
ocular, topical, and oral delivery
Problem solved
The platform is intended to overcome physiological and context-specific delivery barriers that limit RNA therapeutics, including poor stability, insufficient targeting, and lack of microenvironment responsiveness. It provides additional structural options beyond conventional LNPs.; addressing delivery barriers that limit broad clinical translation of RNA therapeutics; providing tunable architectures for RNA encapsulation, site-specific delivery, and controlled release; The platform is presented as a way to improve encapsulation efficiency, stability, targeted delivery, controlled release, and pharmacokinetic performance for diverse therapeutic cargos.; combining polymer-core mechanical strength and sustained release with lipid-shell biocompatibility and drug-loading efficiency; improving targeted delivery; enhancing pharmacokinetic performance
Source:
The platform is intended to overcome physiological and context-specific delivery barriers that limit RNA therapeutics, including poor stability, insufficient targeting, and lack of microenvironment responsiveness. It provides additional structural options beyond conventional LNPs.
Source:
addressing delivery barriers that limit broad clinical translation of RNA therapeutics
Source:
providing tunable architectures for RNA encapsulation, site-specific delivery, and controlled release
Source:
The platform is presented as a way to improve encapsulation efficiency, stability, targeted delivery, controlled release, and pharmacokinetic performance for diverse therapeutic cargos.
Source:
combining polymer-core mechanical strength and sustained release with lipid-shell biocompatibility and drug-loading efficiency
Source:
improving targeted delivery
Source:
enhancing pharmacokinetic performance
Problem links
addressing delivery barriers that limit broad clinical translation of RNA therapeutics
LiteratureThe platform is intended to overcome physiological and context-specific delivery barriers that limit RNA therapeutics, including poor stability, insufficient targeting, and lack of microenvironment responsiveness. It provides additional structural options beyond conventional LNPs.
Source:
The platform is intended to overcome physiological and context-specific delivery barriers that limit RNA therapeutics, including poor stability, insufficient targeting, and lack of microenvironment responsiveness. It provides additional structural options beyond conventional LNPs.
combining polymer-core mechanical strength and sustained release with lipid-shell biocompatibility and drug-loading efficiency
LiteratureThe platform is presented as a way to improve encapsulation efficiency, stability, targeted delivery, controlled release, and pharmacokinetic performance for diverse therapeutic cargos.
Source:
The platform is presented as a way to improve encapsulation efficiency, stability, targeted delivery, controlled release, and pharmacokinetic performance for diverse therapeutic cargos.
enhancing pharmacokinetic performance
LiteratureThe platform is presented as a way to improve encapsulation efficiency, stability, targeted delivery, controlled release, and pharmacokinetic performance for diverse therapeutic cargos.
Source:
The platform is presented as a way to improve encapsulation efficiency, stability, targeted delivery, controlled release, and pharmacokinetic performance for diverse therapeutic cargos.
improving targeted delivery
LiteratureThe platform is presented as a way to improve encapsulation efficiency, stability, targeted delivery, controlled release, and pharmacokinetic performance for diverse therapeutic cargos.
Source:
The platform is presented as a way to improve encapsulation efficiency, stability, targeted delivery, controlled release, and pharmacokinetic performance for diverse therapeutic cargos.
providing tunable architectures for RNA encapsulation, site-specific delivery, and controlled release
LiteratureThe platform is intended to overcome physiological and context-specific delivery barriers that limit RNA therapeutics, including poor stability, insufficient targeting, and lack of microenvironment responsiveness. It provides additional structural options beyond conventional LNPs.
Source:
The platform is intended to overcome physiological and context-specific delivery barriers that limit RNA therapeutics, including poor stability, insufficient targeting, and lack of microenvironment responsiveness. It provides additional structural options beyond conventional LNPs.
Published Workflows
Objective: Develop next-generation lipid-polymer hybrid nanoparticle platforms for RNA therapeutics that overcome delivery barriers and support translatable local or systemic mRNA or siRNA delivery across diverse disease contexts and administration routes.
Why it works: The abstract argues that combining lipid components with biodegradable polymers having tailored functions enables tunable nanoparticle architectures that can jointly improve stability, targeting, encapsulation, and controlled release beyond what conventional LNPs achieve in some contexts.
CD44-mediated targeted deliveryredox-responsive release in the tumor microenvironmentrational material pairingdesign and synthesis of hybrid nanoparticles
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Mechanisms
cd44-mediated targeted deliverycontrolled releaseendosomal escaperedox-responsive releasesustained releaseTranslation ControlTarget processes
manufacturingrecombinationtranslationInput: Chemical
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: externally suppliedimplementation constraint: context specific validationoperating role: delivery
Implementation requires lipid-polymer formulations with biodegradable polymers chosen for specific functions such as structural stability, CD44-mediated targeting, or redox-responsive release. The abstract also indicates that design depends on optimizing formulation properties like RNA loading, uptake, endosomal escape, and targeting efficacy.; requires rational material pairings and design principles; performance depends on optimizing colloidal stability, RNA loading, cellular uptake, endosomal escape, and targeting efficacy; The abstract states that LPHNP design uses polymers, lipids, and surfactants, and discusses fabrication by single-step, emulsification-solvent evaporation, and microfluidic techniques. Functionalized versions may also incorporate ligands, imaging elements, or stimuli-responsive elements.; requires appropriate polymer, lipid, and surfactant selection; fabrication method choice affects scalability and reproducibility; quality by design and advanced manufacturing technologies are needed for clinical and commercial translation
The abstract does not claim that LPHNPs fully solve all RNA delivery barriers in every context. It also notes future challenges, implying remaining translational limitations.; the abstract does not specify a single universally optimal LPHNP architecture; future challenges remain for next-generation translatable RNA delivery platforms; The abstract explicitly notes unresolved challenges in large-scale production, reproducibility, safety, and regulatory standardization.; large-scale production remains a challenge; reproducibility remains a challenge; safety remains a challenge; regulatory standardization remains a challenge
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Source 2primary paper2026MED
Ranked Claims
The LPHNP platforms developed by the authors' laboratory are described as having translational potential across oral, inhaled, intravenous, and intravesical delivery routes and disease models including cancers, inflammatory diseases, and respiratory conditions.
We also provide case studies demonstrating the translational potential of RNA-LPHNPs across various administration routes and disease models, including oral, inhaled, intravenous, and intravesical delivery... These platforms have achieved promising therapeutic efficacy in models of cancers, inflammatory diseases, and respiratory conditions
Conventional lipid nanoparticles have clinical success but still face context-specific delivery barriers including poor stability in blood or gastrointestinal fluids, lack of disease-microenvironment responsiveness, and insufficient cell-type targeting.
Lipid nanoparticles (LNPs) have attracted significant attention due to their clinical success, yet they still struggle to overcome context-specific delivery barriers, such as poor stability in blood or gastrointestinal fluids, lack of disease-microenvironment responsiveness, and insufficient cell-type targeting
Within LPHNP designs, PLGA is used for structural stability, hyaluronic acid for CD44-mediated targeted delivery, and l-cysteine-based poly(disulfide amide) for redox-responsive release in the tumor microenvironment.
By incorporating biodegradable polymers with tailored properties, for example, poly(lactic-co-glycolic acid) (PLGA) for structural stability, hyaluronic acid (HA) for CD44-mediated targeted delivery, and l-cysteine-based poly(disulfide amide) (Cys-PDSA) for redox-responsive release in the tumor microenvironment
The paper highlights rational material pairings and design principles for LPHNPs that optimize colloidal stability, RNA loading, cellular uptake, endosomal escape, and targeting efficacy.
We highlight rational material pairings and design principles that optimize key performance metrics, including colloidal stability, RNA loading, cellular uptake, endosomal escape, and targeting efficacy.
Lipid-polymer hybrid nanoparticles are presented as tunable RNA delivery platforms that integrate RNA encapsulation, site-specific delivery, and controlled RNA release.
these LPHNPs exhibit highly tunable architectures that integrate efficient RNA encapsulation, site-specific delivery, and controlled RNA release
LPHNPs are discussed for non-oncologic ocular, topical, and oral delivery with potential to treat inflammatory, infectious, and autoimmune disorders through sustained release and enhanced therapeutic efficacy.
LPHNPs have therapeutic potential for delivering poorly soluble drugs, phytochemicals, and genetic materials in oncological applications, with synergistic therapeutic outcomes highlighted.
LPHNPs combine polymer-core mechanical strength and sustained-release capacity with lipid-shell biocompatibility and high drug-loading efficiency.
Single-step, emulsification-solvent evaporation, and microfluidic fabrication methods for LPHNPs are discussed in relation to scalability and reproducibility.
Ligand-based functionalization and integration of imaging and stimuli-responsive elements are used with LPHNPs to enhance targeted delivery and create multifunctional theranostic systems.
LPHNP design strategies and architectures can enhance encapsulation efficiency, stability, and targeted delivery of diverse therapeutic agents.
Clinical and commercial translation of next-generation LPHNPs is limited by challenges in large-scale production, reproducibility, safety, and regulatory standardization, which the authors say should be addressed through quality by design approaches and advanced manufacturing technologies.
Approval Evidence
2 sources12 linked approval claimsfirst-pass slug lipid-polymer-hybrid-nanoparticles
Over the past decade, our group has focused on developing novel lipid-polymer hybrid nanoparticles (LPHNPs) for the delivery of RNA therapeutics across diverse biomedical applications.
Source:
Lipid-polymer hybrid nanoparticles (LPHNPs) are the next-generation nanocarriers that integrate the mechanical strength and sustained-release capacity of polymeric cores with the biocompatibility and high drug-loading efficiency of lipid shells.
Source:
application scopesupports
The LPHNP platforms developed by the authors' laboratory are described as having translational potential across oral, inhaled, intravenous, and intravesical delivery routes and disease models including cancers, inflammatory diseases, and respiratory conditions.
We also provide case studies demonstrating the translational potential of RNA-LPHNPs across various administration routes and disease models, including oral, inhaled, intravenous, and intravesical delivery... These platforms have achieved promising therapeutic efficacy in models of cancers, inflammatory diseases, and respiratory conditions
Source:
comparative limitationsupports
Conventional lipid nanoparticles have clinical success but still face context-specific delivery barriers including poor stability in blood or gastrointestinal fluids, lack of disease-microenvironment responsiveness, and insufficient cell-type targeting.
Lipid nanoparticles (LNPs) have attracted significant attention due to their clinical success, yet they still struggle to overcome context-specific delivery barriers, such as poor stability in blood or gastrointestinal fluids, lack of disease-microenvironment responsiveness, and insufficient cell-type targeting
Source:
design principlesupports
Within LPHNP designs, PLGA is used for structural stability, hyaluronic acid for CD44-mediated targeted delivery, and l-cysteine-based poly(disulfide amide) for redox-responsive release in the tumor microenvironment.
By incorporating biodegradable polymers with tailored properties, for example, poly(lactic-co-glycolic acid) (PLGA) for structural stability, hyaluronic acid (HA) for CD44-mediated targeted delivery, and l-cysteine-based poly(disulfide amide) (Cys-PDSA) for redox-responsive release in the tumor microenvironment
Source:
optimization axissupports
The paper highlights rational material pairings and design principles for LPHNPs that optimize colloidal stability, RNA loading, cellular uptake, endosomal escape, and targeting efficacy.
We highlight rational material pairings and design principles that optimize key performance metrics, including colloidal stability, RNA loading, cellular uptake, endosomal escape, and targeting efficacy.
Source:
tool capabilitysupports
Lipid-polymer hybrid nanoparticles are presented as tunable RNA delivery platforms that integrate RNA encapsulation, site-specific delivery, and controlled RNA release.
these LPHNPs exhibit highly tunable architectures that integrate efficient RNA encapsulation, site-specific delivery, and controlled RNA release
Source:
application scopesupports
LPHNPs are discussed for non-oncologic ocular, topical, and oral delivery with potential to treat inflammatory, infectious, and autoimmune disorders through sustained release and enhanced therapeutic efficacy.
Source:
application scopesupports
LPHNPs have therapeutic potential for delivering poorly soluble drugs, phytochemicals, and genetic materials in oncological applications, with synergistic therapeutic outcomes highlighted.
Source:
design propertysupports
LPHNPs combine polymer-core mechanical strength and sustained-release capacity with lipid-shell biocompatibility and high drug-loading efficiency.
Source:
fabrication method propertysupports
Single-step, emulsification-solvent evaporation, and microfluidic fabrication methods for LPHNPs are discussed in relation to scalability and reproducibility.
Source:
functionalization capabilitysupports
Ligand-based functionalization and integration of imaging and stimuli-responsive elements are used with LPHNPs to enhance targeted delivery and create multifunctional theranostic systems.
Source:
performance scopesupports
LPHNP design strategies and architectures can enhance encapsulation efficiency, stability, and targeted delivery of diverse therapeutic agents.
Source:
translation challengesupports
Clinical and commercial translation of next-generation LPHNPs is limited by challenges in large-scale production, reproducibility, safety, and regulatory standardization, which the authors say should be addressed through quality by design approaches and advanced manufacturing technologies.
Source:
Comparisons
Source-stated alternatives
The abstract explicitly contrasts LPHNPs with lipid nanoparticles (LNPs), which have clinical success but still struggle with stability, responsiveness, and cell-type targeting in some settings.; The abstract contrasts different fabrication approaches for LPHNPs, including single-step, emulsification-solvent evaporation, and microfluidic techniques, but does not directly compare LPHNPs against a separate non-hybrid carrier class.
Source:
The abstract explicitly contrasts LPHNPs with lipid nanoparticles (LNPs), which have clinical success but still struggle with stability, responsiveness, and cell-type targeting in some settings.
Source:
The abstract contrasts different fabrication approaches for LPHNPs, including single-step, emulsification-solvent evaporation, and microfluidic techniques, but does not directly compare LPHNPs against a separate non-hybrid carrier class.
Source-backed strengths
highly tunable architectures; integrates efficient RNA encapsulation, site-specific delivery, and controlled RNA release; can be configured with biodegradable polymers for stability, targeting, or stimulus-responsive release; integrates sustained-release capacity with biocompatibility; supports high drug-loading efficiency; can be functionalized with ligands, imaging, and stimuli-responsive elements; has potential across oncologic and non-oncologic applications
Source:
highly tunable architectures
Source:
integrates efficient RNA encapsulation, site-specific delivery, and controlled RNA release
Source:
can be configured with biodegradable polymers for stability, targeting, or stimulus-responsive release
Source:
integrates sustained-release capacity with biocompatibility
Source:
supports high drug-loading efficiency
Source:
can be functionalized with ligands, imaging, and stimuli-responsive elements
Source:
has potential across oncologic and non-oncologic applications
Compared with lipid nanoparticle
The abstract explicitly contrasts LPHNPs with lipid nanoparticles (LNPs), which have clinical success but still struggle with stability, responsiveness, and cell-type targeting in some settings.
Shared frame: source-stated alternative in extracted literature
Strengths here: highly tunable architectures; integrates efficient RNA encapsulation, site-specific delivery, and controlled RNA release; can be configured with biodegradable polymers for stability, targeting, or stimulus-responsive release.
Relative tradeoffs: the abstract does not specify a single universally optimal LPHNP architecture; future challenges remain for next-generation translatable RNA delivery platforms; large-scale production remains a challenge.
Source:
The abstract explicitly contrasts LPHNPs with lipid nanoparticles (LNPs), which have clinical success but still struggle with stability, responsiveness, and cell-type targeting in some settings.
Compared with lipid nanoparticles
The abstract explicitly contrasts LPHNPs with lipid nanoparticles (LNPs), which have clinical success but still struggle with stability, responsiveness, and cell-type targeting in some settings.
Shared frame: source-stated alternative in extracted literature
Strengths here: highly tunable architectures; integrates efficient RNA encapsulation, site-specific delivery, and controlled RNA release; can be configured with biodegradable polymers for stability, targeting, or stimulus-responsive release.
Relative tradeoffs: the abstract does not specify a single universally optimal LPHNP architecture; future challenges remain for next-generation translatable RNA delivery platforms; large-scale production remains a challenge.
Source:
The abstract explicitly contrasts LPHNPs with lipid nanoparticles (LNPs), which have clinical success but still struggle with stability, responsiveness, and cell-type targeting in some settings.
Compared with LNP
The abstract explicitly contrasts LPHNPs with lipid nanoparticles (LNPs), which have clinical success but still struggle with stability, responsiveness, and cell-type targeting in some settings.
Shared frame: source-stated alternative in extracted literature
Strengths here: highly tunable architectures; integrates efficient RNA encapsulation, site-specific delivery, and controlled RNA release; can be configured with biodegradable polymers for stability, targeting, or stimulus-responsive release.
Relative tradeoffs: the abstract does not specify a single universally optimal LPHNP architecture; future challenges remain for next-generation translatable RNA delivery platforms; large-scale production remains a challenge.
Source:
The abstract explicitly contrasts LPHNPs with lipid nanoparticles (LNPs), which have clinical success but still struggle with stability, responsiveness, and cell-type targeting in some settings.
Compared with mRNA-lipid nanoparticles
The abstract explicitly contrasts LPHNPs with lipid nanoparticles (LNPs), which have clinical success but still struggle with stability, responsiveness, and cell-type targeting in some settings.
Shared frame: source-stated alternative in extracted literature
Strengths here: highly tunable architectures; integrates efficient RNA encapsulation, site-specific delivery, and controlled RNA release; can be configured with biodegradable polymers for stability, targeting, or stimulus-responsive release.
Relative tradeoffs: the abstract does not specify a single universally optimal LPHNP architecture; future challenges remain for next-generation translatable RNA delivery platforms; large-scale production remains a challenge.
Source:
The abstract explicitly contrasts LPHNPs with lipid nanoparticles (LNPs), which have clinical success but still struggle with stability, responsiveness, and cell-type targeting in some settings.
Compared with mRNA-loaded lipid nanoparticles
The abstract explicitly contrasts LPHNPs with lipid nanoparticles (LNPs), which have clinical success but still struggle with stability, responsiveness, and cell-type targeting in some settings.
Shared frame: source-stated alternative in extracted literature
Strengths here: highly tunable architectures; integrates efficient RNA encapsulation, site-specific delivery, and controlled RNA release; can be configured with biodegradable polymers for stability, targeting, or stimulus-responsive release.
Relative tradeoffs: the abstract does not specify a single universally optimal LPHNP architecture; future challenges remain for next-generation translatable RNA delivery platforms; large-scale production remains a challenge.
Source:
The abstract explicitly contrasts LPHNPs with lipid nanoparticles (LNPs), which have clinical success but still struggle with stability, responsiveness, and cell-type targeting in some settings.
Ranked Citations
- 1.
- 2.